New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
09:16 EDTXOMAXOMA finalizes plan for gevokizumab Phase 3 clinical program in PG
XOMA announced that based on its meeting with the FDA, the company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum, or PG, a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. During the meeting, the Company and the FDA reviewed the data generated from XOMA's pilot trial in six PG patients. The pilot study was designed to determine if gevokizumab, an IL-1 beta modulating antibody, should be explored in pivotal studies in patients with active PG. XOMA is incorporating the FDA's verbal and written responses regarding the clinical design of the studies into a final Phase 3 program, which it will submit to the Agency for any final comments. The Phase 3 program is expected to include two double-blind, placebo-controlled clinical studies, each of which is designed to enroll approximately 60 patients with active PG. The primary endpoint is complete wound closure of the target ulcer at approximately four months. XOMA anticipates conducting these parallel studies in the United States and several other countries.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
08:40 EDTXOMAXOMA announces license agreement with Novo Nordisk
XOMA (XOMA) announced it has exclusively licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies that up-regulate the insulin receptor to Novo Nordisk A/S (NVO). Under the terms of the agreement, XOMA retains commercialization rights for rare disease indications. Novo Nordisk has an option to add these additional rights in rare diseases to its license. XOMA will receive $5.0M in the form of an upfront payment, and the agreement includes up to $290.0M in additional potential development, regulatory and commercial milestones. In addition, XOMA is eligible to receive tiered royalties on product sales.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use